← All trials
NCT06883162
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 6, 2025
- Primary completion
- Sep 1, 2028
- Completion date
- Jan 1, 2029
- First posted
- Mar 19, 2025
- Last posted
- May 8, 2025
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Medical University of South CarolinaLead sponsor
- Medical University of South CarolinaSponsor investigator
- National Cancer Institute (NCI)Collaborator
- Medical University of South CarolinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.